As of 16 June 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of levothyroxine sodium 12.5 micrograms (mcg) and 25mcg tablets for the management of hypothyroidism of any etiology. The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments from 16 June (Tuesday) to 30 June (Tuesday) 2026

As a preliminary recommendation, the HTA Council recommends the government financing of levothyroxine 12.5mcg and 25mcg. However, due to the substantial budget impact of financing these drugs, the DOH should strongly consider conducting price negotiations to ensure affordability and sustainable access to these treatments.

For the supporting evidence reviewed and discussed by the HTA Council, please refer to the document below.

All comments, inputs, and/or appeals on the above preliminary recommendation may be submitted until 30 June 2026 (Tuesday), for the consideration of the HTA Council, through email at hta@dost.gov.ph. Please use the prescribed form for appeals indicated in the official HTA Philippines website [https://hta.dost.gov.ph/appeals-2/]. Appeals not following the prescribed format and those submitted beyond the deadline shall not be entertained.